DnB Asset Management AS Has $813,000 Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

DnB Asset Management AS decreased its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 35.7% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 6,687 shares of the biotechnology company’s stock after selling 3,719 shares during the quarter. DnB Asset Management AS’s holdings in Sarepta Therapeutics were worth $813,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of the company. Manchester Capital Management LLC grew its position in shares of Sarepta Therapeutics by 86.6% during the 4th quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company’s stock worth $29,000 after buying an additional 110 shares during the period. MassMutual Private Wealth & Trust FSB grew its holdings in Sarepta Therapeutics by 169.6% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 156 shares during the period. Sunbelt Securities Inc. raised its position in shares of Sarepta Therapeutics by 446.2% during the 3rd quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company’s stock valued at $35,000 after acquiring an additional 232 shares during the last quarter. Newbridge Financial Services Group Inc. acquired a new position in shares of Sarepta Therapeutics in the 4th quarter valued at $36,000. Finally, Steward Partners Investment Advisory LLC boosted its position in shares of Sarepta Therapeutics by 164.4% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 312 shares of the biotechnology company’s stock worth $38,000 after purchasing an additional 194 shares during the last quarter. 86.68% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Sarepta Therapeutics news, Director Claude Nicaise sold 2,491 shares of the stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total value of $248,203.24. Following the completion of the sale, the director now owns 27,812 shares in the company, valued at $2,771,187.68. This trade represents a 8.22 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 7.70% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on SRPT. Royal Bank of Canada lowered Sarepta Therapeutics from an “outperform” rating to a “sector perform” rating and decreased their target price for the stock from $161.00 to $87.00 in a research report on Monday. Needham & Company LLC restated a “buy” rating and set a $202.00 price objective on shares of Sarepta Therapeutics in a report on Tuesday, March 18th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $163.00 target price on shares of Sarepta Therapeutics in a report on Tuesday, March 18th. HC Wainwright upgraded shares of Sarepta Therapeutics from a “sell” rating to a “neutral” rating and set a $75.00 price objective for the company in a research report on Wednesday. Finally, Scotiabank reduced their target price on Sarepta Therapeutics from $105.00 to $80.00 and set a “sector perform” rating on the stock in a report on Thursday, March 20th. Six analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $164.05.

Sarepta Therapeutics Stock Up 0.9 %

NASDAQ:SRPT opened at $62.47 on Thursday. Sarepta Therapeutics, Inc. has a twelve month low of $58.50 and a twelve month high of $173.25. The firm has a market capitalization of $6.06 billion, a price-to-earnings ratio of 49.98 and a beta of 0.79. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. The stock’s 50 day moving average price is $99.40 and its two-hundred day moving average price is $114.66.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.